Who are Rhopressa's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Rocklatan 0.02%-0.005% Ophthalmic Solution, VEN 307, Netarsudil Ophthalmic, DE-114 ophthalmic solution.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/netarsudil.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Rhopressa — Competitive Intelligence Brief

Rhopressa (NETARSUDIL) competitive landscape: 4 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Rho Kinase Inhibitor. Area: Cardiovascular.

marketed Rho Kinase Inhibitor rho kinase Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Rhopressa (NETARSUDIL) — Alcon Labs Inc. Netarsudil reduces intraocular pressure by increasing aqueous humor outflow through the trabecular meshwork.

Comparator set (4 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Rhopressa TARGET	NETARSUDIL	Alcon Labs Inc	marketed	Rho Kinase Inhibitor	rho kinase	2017-01-01
Rocklatan 0.02%-0.005% Ophthalmic Solution	Rocklatan 0.02%-0.005% Ophthalmic Solution	Eye Centers of Southeast Texas	marketed	Prostaglandin analog / Rho kinase inhibitor combination	Prostaglandin F receptor (FP receptor) / Rho kinase (ROCK)
VEN 307	VEN 307	Ventrus Biosciences, Inc	phase 3	Rho kinase inhibitor	Rho kinase (ROCK)
Netarsudil Ophthalmic	Netarsudil Ophthalmic	University of the Incarnate Word	marketed	Rho kinase inhibitor	ROCK1/ROCK2, norepinephrine transporter
DE-114 ophthalmic solution	DE-114 ophthalmic solution	Santen Pharmaceutical Co., Ltd.	phase 3	Rho kinase inhibitor	ROCK (Rho-associated coiled-coil containing protein kinase)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Rho Kinase Inhibitor class)

Alcon Labs Inc · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Rhopressa — Competitive Intelligence Brief. https://druglandscape.com/ci/netarsudil. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab